CLINICAL_TRIALS
trial_result
· 2024-08-09
Clinical Trial Update: Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy [Phase 2]
Summary
A Phase 2 study evaluating the oral Factor D inhibitor ALXN2050 as monotherapy in paroxysmal nocturnal hemoglobinuria was terminated, with results posted in 202…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Status: TERMINATED | Results posted: 2024-08-09